Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 4/2006

01-04-2006 | Adis Drug Profile

Ziconotide

A Viewpoint by Peter Staats

Author: Peter Staats

Published in: CNS Drugs | Issue 4/2006

Login to get access

Excerpt

Chronic severe pain is increasingly recognised as a significant public health issue and an unmet medical need. Delivery of analgesics through the intrathecal route is accepted by pain management specialists as the next step for those unresponsive to standard oral and systemic analgesic therapy.[1‐4] However, opioids, the most commonly used intrathecal analgesics, are limited in their effectiveness by a number of factors: …
Literature
1.
Ventafridda V, Spoldi E, Caraceni A, et al. Intraspinal morphine for cancer pain. Acta Anaesthesiol Scand Suppl 1987; 85: 47–53PubMedCrossRef
2.
Staats P. Cancer pain: beyond the ladder. J Back Musculoskeletal Rehabil 1998; 10: 69–80CrossRef
3.
Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy: a survey of clinical trends and decision making. J Pain Symptom Manage 2000; 20(2): S4–11PubMedCrossRef
4.
Jacox A, Carr D, Payne R. New clinical-practice guideline for the management of pain in patients with cancer. N Engl J Med 1994; 330: 651–5PubMedCrossRef
5.
Mathur VS, McGuire D, Bowersox S, et al. Neuronal N-type calcium channels: new prospect in pain therapy. Pharm News 1998; 5: 25–9
6.
Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004 Jan 7; 291(1): 63–70PubMedCrossRef
Metadata
Title
Ziconotide
A Viewpoint by Peter Staats
Author
Peter Staats
Publication date
01-04-2006
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2006
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200620040-00008

Other articles of this Issue 4/2006

CNS Drugs 4/2006 Go to the issue

Leading Article

Tailoring Nicotine Replacement Therapy

Commentary

The SOHO (Schizophrenia Outpatient Health Outcome) Study

Therapy in Practice

Long-Term Prophylaxis in Bipolar Disorder

Original Research Article

Assessing Therapeutic Efficacy in a Progressive Disease

Adis Drug Profile

Ziconotide

Leading Article

Aromatherapy in the Management of Psychiatric Disorders